Veklury

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0048	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	31/01/2023		SmPC	To change the shelf life in section 6.3, SmPC from 3 years to 4 years.
II/0043	Update of section 5.1 of the SmPC in order to update information based on the final virology report (PC-	15/12/2022	05/01/2023	SmPC	SmPC new text

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	540-2040) for study GS-US-540-9012 to fulfil the recommendation by CHMP in the procedure EMEA/H/C/005622/II/0016; this is a phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of RDV in an outpatient setting in participants with confirmed COVID-19 who were at risk for disease progression. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				Update of section 5.1 of the SmPC in order to update virology data of study GS-US-540-9012. No significant changes in antiviral activity were determined (<2.3 fold change in EC50 compared to reference strain) for treatment emergent substitutions in Nsp8, Nsp 10, Nsp12, Nsp13 and Nsp 14 with one exception (the amino acid substitution A376V in Nsp12 observed in one patient showed an EC50 fold-change of 12.6). Overall, based on the submitted data RDV maintained a similar antiviral effect in vitro. For more information, please refer to the Summary of Product Characteristics.
PSUSA/10840 /202205	Periodic Safety Update EU Single assessment - remdesivir (Veklury)	01/12/2022	n/a		PRAC Recommendation - maintenance
II/0042	Update of section 5.1 to provide in vitro data on the antiviral activity of remdesivir against the Omicron subvariants BA.2.12.1, BA.4 and BA.5 following procedure II/0034/G based on in vitro study "Remdesivir Antiviral Activity against Omicron Subvariants BA.2.12.1, BA.4, and BA.5 in A549-hACE2-TMPRSS2 Cells". C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	10/11/2022	21/11/2022	SmPC	SmPC new text Update of 5.1 of the SmPC in order to add new data related to the antiviral activity of remdesivir against COVID-19. For the Omicron subvariants tested, BA.2.12.1, BA.4 and BA.5, remdesivir showed no decrease in susceptibility, thus supporting its use for the treatment of COVID-19 considering the previously named SARS-CoV-2 variants(in circulation at the time of this assessment). For more information, please refer to the Summary of Product Characteristics.
II/0037/G	This was an application for a group of variations.	13/10/2022	20/10/2022	SmPC and PL	SmPC new text

	Grouped variations to update sections 4.5 and 5.2 of the SmPC to update prescribing information related to interactions with other medicinal products, effect of intrinsic factors and COVID-19 disease on the pharmacokinetics (PK) of Veklury® and its metabolites in the adult population. This variation covers the Recommendations 9,11 ,12 and 13 listed at the time of the conditional marketing authorization (EMEA/H/C/005622/0000) for Veklury®. Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some linguistic amendments. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance				The PI has been updated to include more data regarding the interaction of remdesivir with other medicinal products in 4.5. In addition, new pharmacokinetic data of remdesivir in healthy volunteers and patients with COVID 19 are included in 5.2. For more information, please refer to the Summary of Product Characteristics.

	data				
II/0035/G	This was an application for a group of variations. Grouped application of two Extensions of indication to include: - treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment, based on interim results from Study GS-US-540-5823; a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Remdesivir in participants from birth to <18 years of age with COVID-19; - treatment of paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID 19, based on data from 8 adolescent patients who were included in Study GS-US-540-9012, which was initially assessed by the CHMP as part of procedure II/16 (Extension of Indication to include treatment of adults). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet as well as the instructions for healthcare professionals have been updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Version 5.0 of	15/09/2022	16/09/2022	SmPC and PL	Please refer to Scientific Discussion Veklury /H/C/005622/II/0035/G.

	the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IA/0041	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	24/08/2022	n/a		
II/0034/G	This was an application for a group of variations. Grouping variation to update section 5.1 of the SmPC in relation to information regarding the antiviral activity of Veklury. This submission of the final results of study ACTT-1 with the final sequencing and phenotyping analysis and the full virology report including activity against variants is related to the Specific Obligation 012. Furthermore, Annex II is updated accordingly to reflect the fulfilment of the specific obligations following this submission. Finally, the MAH provided data on the alternative method (i.e., the SARS-CoV-2 replicon system) that can be utilised to allow further testing of the Nsp12 mutation A547V as requested in REC 027 that is also considered fulfilled. The Package Leaflet and the RMP (version 4.0) are updated accordingly. Furthermore, the CHMP is of the opinion that in light	21/07/2022	08/08/2022	SmPC, Annex II and PL	Please refer to Scientific Discussion "Veklury EMEA/H/C/005622/II/0034/G" SmPC new text As a consequence of this variation, section 5.1 of the SmPC is updated with new virological data including the virological activity of Veklury against Omicron. Furthermore, the last specific obligation for this product is considered fulfilled and, therefore, it is deleted from Annex II. For more information, please refer to the Summary of Product Characteristics.

	of all the data generated throughout all the specific obligations providing a comprehensive dataset, the benefit-risk balance of the above- mentioned medicinal product remains favourable and also considering the evidence of compliance with all specific obligations, the CHMP recommends the granting of a marketing authorisation in accordance with Article 14(1) of Regulation No 726/2004. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
PSUSA/10840 /202111	Periodic Safety Update EU Single assessment - remdesivir (Veklury)	23/06/2022	19/07/2022	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10840/202111.
II/0036	Update of sections 4.4 and 5.1 of the SmPC in order to update information regarding the baseline serostatus of patients included in the Study GS US 540 9012 (Phase 3, randomized, double blind, placebo controlled study to evaluate RDV treatment of COVID 19 in an outpatient setting) listed as a Recommendation (number 24) within the procedure EMA/ 005622/II/0016 that led to the extension of indication of remdesivir to adults with confirmed COVID 19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.	16/06/2022	19/07/2022	SmPC	SmPC new text Within variation, the MAH submitted a post-hoc subgroup analysis of the primary and secondary efficacy endpoint stratified by baseline serostatus of study GS-US-540-9012. However, no conclusion can be made on efficacy in the subgroups stratified by serostatus due to the small number of patients with known serostatus and overall low event rates. No new safety signal has been identified. For more information, please refer to the Summary of Product Characteristics.

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
IA/0038/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	10/06/2022	n/a		
IA/0039	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	09/06/2022	n/a		
R/0031	Renewal of the marketing authorisation.	24/03/2022	12/04/2022		The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Veklury, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.

II/0026/G	This was an application for a group of variations. Grouped variation updating sections 4.6, 5.2 and 5.3 of the SmPC in order to update information in these sections considering new nonclinical data requested at the time of the initial conditional marketing application (EMEA/H/C/005622). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	03/02/2022	12/04/2022	SmPC	Sections 4.6,5.2 and 5.3 of the SmPC to update reproductive information from animal studies; biotransformation with metabolization details and toxicology regarding major metabolite M27.
IB/0032	B.II.e.z - Change in container closure system of the Finished Product - Other variation	28/01/2022	n/a		
II/0016	Extension of indication to include treatment of adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An update of the Risk Management Plan (RMP) (Version 3.0) has been also submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	16/12/2021	20/12/2021	SmPC and PL	Please refer to Scientific Discussion EMEA/H/C/005622/II/0016

II/0028/G	This was an application for a group of variations. C.I.4. Grouping variation to Update of section 5.1 of the SmPC in order to add information related to in vitro testing reports of B.1.1.28 and B.1.617 variants with additional provision of the cell culture resistance report to further understand the antiviral activity of Remdesivir. They are listed as part of the specific obligation (SOB 012) in the Annex II of the renewal procedure EMEA/H/C/005622/R/0015 for Veklury. C.I.13.Grouping variation for the submission of the virology reports for GS-US-540-5773 and GS-US-540-5774 studies and the submission of the ACTT-1 final viral load analysis included as part of the specific obligation (SOB 012) in the Annex II of the renewal procedure EMEA/H/C/005622/R/0015 for Veklury. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	16/12/2021	20/12/2021	SmPC	SmPC new text Based on in vitro testing, remdesivir retained similar antiviral activity and therefore no reduction in susceptibility (≤1.5-fold change) against clinical isolates of SARS-CoV-2 variants containing the P323L substitution in the viral polymerase including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2). No clinical data are available on the development of SARS-CoV 2 resistance to Remdesivir, however, in vitro data on resistance development has been provided and updated. For more information, please refer to the Summary of Product Characteristics.

PSUSA/10840 /202105	Periodic Safety Update EU Single assessment - remdesivir (Veklury)	02/12/2021	n/a		PRAC Recommendation - maintenance
IB/0029	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	12/11/2021	20/12/2021	Annex II	
IG/1456	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	08/11/2021	n/a		
II/0025/G	This was an application for a group of variations. Update of section 5.1 of the SmPC with nonclinical results following final study reports addressing the activity of remdesivir in additional cell lines and chloroquine/hydroxychloroquine antagonism (fulfilment of 3 components of the Specific Obligation SOB 012 from EMEA/H/C/005622/R/0015). In addition, the Marketing authorisation holder (MAH) took the opportunity to submit the interim results of the non-clinical studies related to the characterisation of clinical isolates and/or recombinant viruses with P323L, A97V, and A547V substitutions. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/10/2021	20/12/2021	SmPC	The interim results of the analysis of the antiviral activity of remdesivir on RdRp/Nsp12 A97V, P323L, and D484Y mutants indicates that these recombinant mutants are still susceptible to remdesivir as no significant change in EC50 values was found. Secondly, the antiviral activity of remdesivir against a nanoluciferase-expressing SARS-CoV-2 construct in a human alveolar epithelial cell line A549 expressing the human ACE2 receptor (A549-hACE2) show inhibition of in vitro replication with an EC50 value of 0.115 µM in this human alveolar cell line. The results are consistent with the results achieved in other cell types and thereby confirm the in vitro antiviral activity of remdesivir against SARS-CoV-2. Finally, the in vitro studies show that co-incubation of remdesivir with Chloroquine (CQ) or Hydroxychloroquine (HCQ) results in a reduced formation of RDV-TP in various cell types. This observed reductions in RDV-TP in the presence of CQ or HCQ indicates a potential antagonistic

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				effect on remdesivir metabolism to its active triphosphate. SmPC new text Section 5.1 Pharmacodynamic Properties / Antiviral Activity of the SmPC is being updated to include new data on the antiviral activity of remdesivir in a human alveolar epithelial cell line (A549-hACE2). The results are consistent with the results achieved in other cell types and thereby confirm the in vitro antiviral activity of remdesivir against SARS-CoV-2. For more information, please refer to the Summary of Product Characteristics
IA/0027/G	This was an application for a group of variations. B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	23/09/2021	n/a		
PSUSA/10840 /202011	Periodic Safety Update EU Single assessment - remdesivir (Veklury)	24/06/2021	20/08/2021	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10840/202011.
IB/0023	C.I.11.z - Introduction of, or change(s) to, the	03/08/2021	20/12/2021	Annex II	

	obligations and conditions of a marketing authorisation, including the RMP - Other variation				
IA/0022	B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure	23/07/2021	n/a		
IB/0020/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch	08/07/2021	n/a		

	control/testing takes place B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size				
IB/0021/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	01/07/2021	n/a		
R/0015	Renewal of the marketing authorisation.	20/05/2021	24/06/2021	SmPC, Annex II, Labelling and PL	The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Veklury, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. Within this procedure and update on sections 4.8, 5.1, 5.2 of the SmPC has been done to mainly reflect the update in

					the frequency of anaphylaxis as not know and the prothrombin time prolonged as very common; to add updated data for the ACCT1 study and study 5773;to add more distribution data plus an update of the Annex II to delete the SOBs fulfilled and to reflect on the postponing of the submission of the virology report by December 2021. PL was modified accordingly. Finally, editorial changes and a linguistic review have been also performed. The RMP has been also updated (last version 2.0)
IB/0019/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	28/05/2021	n/a		
IB/0018/G	This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and	19/05/2021	n/a		

	Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation				
II/0013/G	This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a	22/04/2021	n/a		

	starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation				
IA/0014/G	This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	21/12/2020	n/a		
II/0012	Update of section 4.1 of the SmPC to change the indication as a result of the assessment of the final D28 mortality data by ordinal scale categories of Study COUS-540-5776 (NIAID-ACTT1), listed as a Specific Obligation ('SOB 013') in the Annex II of the Product Information, in order to confirm the efficacy and safety of remdesivir in patients on Invasive Mechanical Ventilation and Extracorporeal Membrane Oxygenation (IMV/ECMO). Consequently section 5.1 of the SmPC is also updated to reflect the final study results. Furthermore, Annex II is updated to remove the completed specific obligation. The package leaflet is updated accordingly.	10/12/2020	21/12/2020	SmPC, Annex II and PL	Please refer to Scientific Discussion Veklury/H/C/005622/II/0012

	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
IB/0010	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	30/11/2020	18/12/2020	Annex II	
IB/0011/G	This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation	26/11/2020	18/12/2020	Annex II	
IB/0009/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other	26/11/2020	18/12/2020	Annex II	

	changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
IB/0008/G	This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation	26/11/2020	18/12/2020	Annex II	

IB/0007/G	This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation	26/11/2020	18/12/2020	Annex II	
IB/0006	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	26/11/2020	18/12/2020	Annex II	
IB/0005	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	26/11/2020	18/12/2020	Annex II	
IB/0003/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits	26/11/2020	18/12/2020	Annex II	

	B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits				
IB/0002/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits	26/11/2020	18/12/2020	Annex II	
IB/0004	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	29/09/2020	18/12/2020	Annex II	
IB/0001	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	04/09/2020	18/12/2020	Annex II	